IRIS
CESARO, ARTURO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 6.326
AS - Asia 3.297
NA - Nord America 2.599
SA - Sud America 496
AF - Africa 55
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 2
Totale 12.777
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 4.858
US - Stati Uniti d'America 2.528
SG - Singapore 1.172
CN - Cina 712
VN - Vietnam 531
IE - Irlanda 487
HK - Hong Kong 432
IT - Italia 404
BR - Brasile 401
DE - Germania 159
KR - Corea 148
GB - Regno Unito 137
IN - India 106
AR - Argentina 47
FR - Francia 43
BD - Bangladesh 36
MX - Messico 33
AT - Austria 31
JP - Giappone 28
CA - Canada 27
GR - Grecia 27
UA - Ucraina 27
SE - Svezia 24
FI - Finlandia 23
NL - Olanda 22
ID - Indonesia 21
TR - Turchia 21
ES - Italia 17
BE - Belgio 16
PL - Polonia 15
EG - Egitto 14
IQ - Iraq 14
CO - Colombia 12
EC - Ecuador 11
MA - Marocco 11
PK - Pakistan 11
ZA - Sudafrica 11
LT - Lituania 9
CL - Cile 7
VE - Venezuela 7
SA - Arabia Saudita 6
TH - Thailandia 6
TN - Tunisia 6
UZ - Uzbekistan 6
IR - Iran 5
KZ - Kazakistan 5
IL - Israele 4
JM - Giamaica 4
JO - Giordania 4
NP - Nepal 4
PA - Panama 4
PH - Filippine 4
TW - Taiwan 4
UY - Uruguay 4
AZ - Azerbaigian 3
BG - Bulgaria 3
CH - Svizzera 3
CR - Costa Rica 3
DK - Danimarca 3
KE - Kenya 3
PE - Perù 3
PY - Paraguay 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
AM - Armenia 2
BY - Bielorussia 2
EU - Europa 2
KG - Kirghizistan 2
MY - Malesia 2
NG - Nigeria 2
NO - Norvegia 2
OM - Oman 2
PT - Portogallo 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
AU - Australia 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
BW - Botswana 1
CI - Costa d'Avorio 1
CZ - Repubblica Ceca 1
DZ - Algeria 1
EE - Estonia 1
ET - Etiopia 1
GA - Gabon 1
GH - Ghana 1
HR - Croazia 1
IS - Islanda 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
NZ - Nuova Zelanda 1
PS - Palestinian Territory 1
RO - Romania 1
SN - Senegal 1
SY - Repubblica araba siriana 1
UG - Uganda 1
Totale 12.777
Salva come PNG Salva come JPEG
Città #
Moscow 1.777
San Jose 616
Singapore 563
Dublin 476
Hong Kong 426
Santa Clara 364
Chandler 237
Ashburn 182
Ho Chi Minh City 176
Hefei 170
Seoul 144
Hanoi 131
New York 107
Beijing 94
Naples 78
The Dalles 77
Bengaluru 68
Princeton 51
Roxbury 51
Los Angeles 46
Da Nang 41
Jacksonville 40
Milan 37
Bremen 34
Nuremberg 34
Dallas 32
Cambridge 30
São Paulo 28
Council Bluffs 25
Des Moines 23
Medford 23
Orem 22
Falkenstein 21
Munich 20
Mexico City 19
Haiphong 18
Boardman 16
Brussels 16
Aversa 14
Rio de Janeiro 14
Rome 14
Tokyo 14
Frankfurt am Main 13
Helsinki 13
Ann Arbor 12
Hyderabad 12
Memphis 12
Vienna 12
Guangzhou 11
Wilmington 11
Hải Dương 10
Nanjing 10
San Francisco 10
Amsterdam 9
Chicago 9
Thái Nguyên 9
Toronto 9
Turin 9
Warsaw 9
Belo Horizonte 8
Brooklyn 8
Campinas 8
Curitiba 8
Ercolano 8
London 8
Nha Trang 8
Ninh Bình 8
Shenzhen 8
Sivas 8
Thái Bình 8
Cairo 7
Caserta 7
Dhaka 7
Houston 7
Jakarta 7
Jinan 7
Atlanta 6
Baghdad 6
Brasília 6
Can Tho 6
Montreal 6
Phoenix 6
Salerno 6
Stockholm 6
Bangkok 5
Belluno 5
Biên Hòa 5
Bologna 5
Buenos Aires 5
Bắc Ninh 5
Bến Tre 5
Chennai 5
Columbus 5
Florence 5
Guayaquil 5
Hangzhou 5
Islamabad 5
Johannesburg 5
Lappeenranta 5
Madrid 5
Totale 6.807
Salva come PNG Salva come JPEG
Nome #
Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience 182
Advanced Heart Failure in Special Population—Pediatric Age 176
Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease 164
Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry 161
Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition 159
Lomitapide in homozygous familial hypercholesterolemia: cardiology perspective from a single-center experience 158
Antithrombotic therapy in patients with atrial high-rate episodes (AHREs): Current evidence and open questions 156
Adherence to PCSK9 inhibitors in high cardiovascular risk patients in real-world setting: results from a single-center experience and comparison with statin therapy 154
Diagnosis and Management of Cardiovascular Involvement in Fabry Disease 152
New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia 149
Childhood obesity: An overview of laboratory medicine, exercise and microbiome 146
Alcohol Septal Ablation in Patients with Hypertrophic Obstructive Cardiomyopathy: A Contemporary Perspective 144
Reduction of new onset of atrial fibrillation in patients treated with semaglutide: an updated systematic review and meta regression analysis of randomized controlled trials 142
Antithrombotic Therapy Optimization in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention 137
Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry 136
ICARUS score for predicting peri-procedural bleeding in patients undergoing percutaneous coronary intervention with cangrelor 133
Impact of gliflozins on cardiac remodeling in patients with type 2 diabetes mellitus & reduced ejection fraction heart failure: A pilot prospective study. GLISCAR study 131
Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry) 131
Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry 131
New frontiers in antiplatelet therapy: guided therapy and de-escalation after acute coronary syndrome or percutaneous coronary intervention 130
The Role of Genetic Testing in Patients with Heritable Thoracic Aortic Diseases 130
SGLT-2 inhibitors and in-stent restenosis-related events after acute myocardial infarction: an observational study in patients with type 2 diabetes 128
De-escalation strategies in patients with acute coronary syndrome: a step towards precision medicine 128
Atrial Fibrillation, Heart Failure Phenotypes, and Mortality Risk in the Nationwide START Registry: A Propensity Score Matching Analysis 127
Coronary Physiology Assessment for the Diagnosis and Treatment of Coronary Artery Disease 127
Low-Dose Ticagrelor in Patients With High Ischemic Risk and Previous Myocardial Infarction: A Multicenter Prospective Real-World Observational Study 127
Multidisciplinary In-Depth Investigation in a Young Athlete Suffering from Syncope Caused by Myocardial Bridge 126
Multimodality Imaging in Arrhythmogenic Left Ventricular Cardiomyopathy 125
Evidence of an anti-inflammatory effect of PCSK9 inhibitors within the human atherosclerotic plaque 124
Immune-Checkpoint Inhibitor-Related Myocarditis: Where We Are and Where We Will Go 123
Role of LipoprotEin(a) in CardiovascuLar diseases and premature acute coronary syndromes (RELACS study): Impact of Lipoprotein(a) levels on the premature coronary event and the severity of coronary artery disease 123
Cardiac involvement in systemic sclerosis: 'early diagnosis-early management' approach 123
Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease 123
GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes 123
Long-Term Antithrombotic Therapy in Patients with Atrial Fibrillation and Percutaneous Coronary Intervention 122
How do cardiologists select patients for dual antiplatelet therapy continuation beyond 1 year after a myocardial infarction? Insights from the EYESHOT Post-MI Study 122
Discrepancies Between Physician-Perceived and Calculated Cardiovascular Risk in Primary Prevention: Implications for LDL-C Target Achievement and Appropriate Lipid-Lowering Therapy 119
Visceral adipose tissue and residual cardiovascular risk: a pathological link and new therapeutic options 118
Functional assessment of coronary stenosis: an overview of available techniques. Is quantitative flow ratio a step to the future? 116
Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry 113
Ticagrelor monotherapy after acute coronary syndrome: lessons from the ULTIMATE-DAPT trial 113
Antithrombotic Therapy after TAVI: Evidence, Discordance, and Clinical Implications 113
Circulating culprit or therapeutic bullseye: lipoprotein(a) in cardiovascular risk assessment and novel therapeutic prospects 113
SARS-COV-2 colonizes coronary thrombus and impairs heart microcirculation bed in asymptomatic SARS-CoV-2 positive subjects with acute myocardial infarction 112
Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: Insight from SGLT2-I AMI PROTECT registry 109
Ipercolesterolemia e referti di laboratorio: documento congiunto della Società Italiana di Cardiologia (SIC) e Società Italiana di Biochimica Clinica e Biologia Molecolare Clinica - Medicina di Laboratorio (SIBioC) 109
The impact of SARS-CoV-2 treatment on the cardiovascular system: an updated review 108
Escalation and De-Escalation of Antiplatelet Therapy after Acute Coronary Syndrome or PCI: Available Evidence and Implications for Practice 108
Von Willebrand Factor as a Novel Player in Valvular Heart Disease: From Bench to Valve Replacement 108
Early-onset MINOCA: Prognostic implications and considerations for practice 108
A pragmatic approach for thrombotic prevention after acute coronary syndromes 107
Design of the PERSEO Registry on the management of patients treated with oral anticoagulants and coronary stent 105
Dietary thiols: A potential supporting strategy against oxidative stress in heart failure and muscular damage during sports activity 105
Improving adherence to Ticagrelor in patients after acute coronary syndrome: Results from the PROGRESS trial 104
In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study 103
Use of bempedoic acid for LDL cholesterol lowering and cardiovascular risk reduction: a consensus document from the Italian study group on atherosclerosis, thrombosis and vascular biology 102
[Long COVID: nosographic aspects and clinical epidemiology] 101
Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and atrial thrombosis: An appraisal of current evidence 101
Coronary stent thickness: thinner is (always) better for all lesions? 101
The Biological Role of Vitamins in Athletes’ Muscle, Heart and Microbiota 101
Understanding the role of coronary artery revascularization in patients with left ventricular dysfunction and multivessel disease 101
Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies 100
Sex Differences in Diagnosis, Treatment, and Cardiovascular Outcomes in Homozygous Familial Hypercholesterolemia 99
Risk Scores of Bleeding Complications in Patients on Dual Antiplatelet Therapy: How to Optimize Identification of Patients at Risk of Bleeding after Percutaneous Coronary Intervention 99
Efficacy, safety, adherence and persistence of PCSK9 inhibitors in clinical practice: A single country, multicenter, observational study (AT-TARGET-IT) 99
Diagnosis of Fabry Disease in a Patient with a Surgically Repaired Congenital Heart Defect: When Clinical History and Genetics Make the Difference 96
AZALEA–TIMI 71 trial: less bleeding with abelacimab compared to rivaroxaban in atrial fibrillation, but stroke prevention is uncertain 95
Beyond the left ventricle: Why the right heart matters in Takotsubo syndrome 94
Differential effects of the phosphodiesterase inhibition in chronic heart failure depending on the echocardiographic phenotype (HFREF or HFpEF): A meta-analysis 94
Artificial intelligence in cardiovascular prevention: new ways will open new doors 93
ECG analysis in patients with acute coronary syndrome undergoing invasive management: rationale and design of the electrocardiography sub-study of the MATRIX trial 93
Does Accidental Overcorrection of Symptomatic Hyponatremia in Chronic Heart Failure Require Specific Therapeutic Adjustments for Preventing Central Pontine Myelinolysis? 93
null 93
Intravenous antiplatelet therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention 92
The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy 92
Potential role of imaging markers in predicting future disease expression of arrhythmogenic cardiomyopathy 92
Secondary Prevention and Extreme Cardiovascular Risk Evaluation (SEVERE-1), Focus on Prevalence and Associated Risk Factors: The Study Protocol 92
The Impact of Physical Exercise on Obesity in a Cohort of Southern Italian Obese Children: Improvement in Cardiovascular Risk and Immune System Biomarkers 91
Letter by Calabrò et al Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)" 90
Peripheral arterial disease has a strong impact on cardiovascular outcome in patients with acute coronary syndromes: from the START Antiplatelet registry 90
Left atrial and auricular thrombosis in patients with atrial fibrillation: from pathophysiology to treatment 89
Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk 89
Exercise, immune system, nutrition, respiratory and cardiovascular diseases during COVID-19: A complex combination 88
How has COVID-19 impacted the care of patients with acute coronary syndromes? 87
Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes and Coronary Artery Disease: Translating the Benefits of the Molecular Mechanisms of Gliflozins into Clinical Practice 87
Methicillin-resistant staphylococcus aureus: Risk for general infection and endocarditis among athletes 87
Epigenetic mechanisms underlying the beneficial effects of cardiac rehabilitation. An overview from the working groups of “cellular and molecular biology of the heart” and “cardiac rehabilitation and cardiovascular prevention” of the Italian Society of Cardiology (SIC) 86
Impact of Gliflozins on Right Heart Remodeling in Italian Patients with Type 2 Diabetes and Heart Failure: Results from the GLISCAR Real-World Study 85
Impact of Regular Physical Activity on Aortic Diameter Progression in Paediatric Patients with Bicuspid Aortic Valve 85
Eligibility for and practical implications of Semaglutide in overweight and obese patients with acute coronary syndrome 84
Reduction of cerebrovascular and peripheral events with PCSK9 inhibitors: Does it just depend on the lowering of the low-density lipoprotein? 84
The Management of Myocardial Injury Related to SARS-CoV-2 Pneumonia 84
Transradial access versus transfemoral access: a comparison of outcomes and efficacy in reducing hemorrhagic events 84
Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey 82
Reply to SGLT-2 inhibitors: Post-infarction interventional effects 80
Polymer-free versus biodegradable-polymer drug-eluting stent in patients undergoing percutaneous coronary intervention: an assessor-blind, non-inferiority, randomised controlled trial 80
Lipid-lowering therapy in patients with coronary artery disease undergoing percutaneous coronary interventions in Italy: an expert opinion paper of Interventional Cardiology Working Group of Italian Society of Cardiology 80
Does a strict glycemic control during acute coronary syndrome play a cardioprotective effect? Pathophysiology and clinical evidence 79
Implementation of guideline‐directed medical therapy in patients with heart failure with reduced ejection fraction (OpTIMa‐HF Registry) 79
Impact of lipoprotein(a) levels on recurrent cardiovascular events in patients with premature coronary artery disease 79
Totale 11.136
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.210
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.210
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20219 0 0 0 0 0 0 0 0 0 0 0 9
2021/2022430 9 3 8 17 104 10 10 41 9 55 37 127
2022/2023863 84 56 19 59 77 46 2 57 428 5 14 16
2023/2024513 28 17 20 24 129 111 19 12 4 29 13 107
2024/20251.804 8 13 2 54 251 207 231 170 259 276 172 161
2025/20269.199 359 526 487 418 678 4.569 606 589 364 298 181 124
Totale 13.069